XML 81 R70.htm IDEA: XBRL DOCUMENT
v3.25.3

Contingencies and Certain Commitments - Patent Litigation (Details) $ in Millions | 1 Months Ended |
--- | --- | ---
Jul. 31, 2025 patent | Mar. 30, 2025 patent | Feb. 28, 2025 patent | Aug. 31, 2024 patent | Jul. 31, 2024 patent | Apr. 30, 2024 patent | Mar. 31, 2024 patent | Nov. 30, 2023 patent | May 31, 2023 patent | Apr. 30, 2023 patent | Sep. 30, 2022 patent | Aug. 31, 2022 patent | Jul. 31, 2022 patent | Sep. 28, 2025 USD ($)
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Threshold for disclosure of proceedings under environmental laws | $ |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1
Comirnaty [Member] | Alnylam Patent Infringement Case [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency, number of patents allegedly infringed upon |  |  |  |  |  |  |  |  | 4 |  |  |  |  |
Loss contingency, number of patents dismissed |  |  | 1 |  |  |  |  |  |  |  |  |  |  |
Comirnaty [Member] | ModernaTX U.S. Patent Infringement Case [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency, number of patents allegedly infringed upon |  |  |  |  |  |  |  |  |  |  |  | 3 |  |
Loss contingency, patents ruled invalid |  | 2 |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency, patents under review |  |  |  |  |  |  | 2 |  |  |  |  |  |  |
Comirnaty [Member] | ModernaTX European Patent Infringement Case [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency, number of patents allegedly infringed upon |  |  |  |  |  |  |  |  |  |  | 2 | 2 |  |
Loss contingency, patents allegedly infringed and subsequently revoked |  |  |  |  |  |  |  | 1 |  |  |  |  |  |
Loss contingency, patents ruled invalid and subsequently revoked |  |  |  |  | 1 |  |  |  |  |  |  |  |  |
Comirnaty [Member] | Arbutus and Genevant U.S. Patent Infringement Case [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency, number of patents allegedly infringed upon |  |  |  |  |  |  |  |  |  | 5 |  |  |  |
Comirnaty [Member] | GlaxoSmithKline Biologics SA and GlaxoSmithKline LLC US Patent Infringement Case [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency, number of patents allegedly infringed upon |  |  |  | 3 |  | 5 |  |  |  |  |  |  |  |
Comirnaty [Member] | GlaxoSmithKline Biologics SA And GlaxoSmithKline LLC Ireland Patent Infringement Case [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency, number of patents allegedly infringed upon | 3 |  |  |  |  |  |  |  |  |  |  |  |  |
Comirnaty [Member] | GlaxoSmithKline Biologics SA And GlaxoSmithKline LLC Unified Patent Court Patent Infringement Case [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency, number of patents allegedly infringed upon | 2 |  |  |  |  |  |  |  |  |  |  |  |  |
Comirnaty [Member] | Pfizer, BioNTech and BioNTech Manufacturing GmbH Versus CureVac, Judgment of Non-Infringement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency, number of patents not infringed |  |  |  |  |  |  |  |  |  |  |  |  | 3 |
Loss contingency, number of patents found infringed |  |  |  |  |  |  |  |  | 3 |  |  |  |  |

X
- Definition Loss Contingency, Patents Allegedly Infringed And Subsequently Revoked, Number + References No definition available. + Details
Name: | pfe_LossContingencyPatentsAllegedlyInfringedAndSubsequentlyRevokedNumber
Namespace Prefix: | pfe_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Loss Contingency, Patents Dismissed + References No definition available. + Details
Name: | pfe_LossContingencyPatentsDismissed
Namespace Prefix: | pfe_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Loss Contingency, Patents Ruled Invalid + References No definition available. + Details
Name: | pfe_LossContingencyPatentsRuledInvalid
Namespace Prefix: | pfe_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Loss Contingency, Patents Ruled Invalid And Subsequently Revoked, Number + References No definition available. + Details
Name: | pfe_LossContingencyPatentsRuledInvalidAndSubsequentlyRevokedNumber
Namespace Prefix: | pfe_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Loss Contingency, Patents Under Review + References No definition available. + Details
Name: | pfe_LossContingencyPatentsUnderReview
Namespace Prefix: | pfe_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Site Contingency, Regulatory Proceedings, Disclosure Threshold + References No definition available. + Details
Name: | pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483049/450-30-50-1 + Details
Name: | us-gaap_GainContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of another entity's patents that the entity has allegedly infringed. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details
Name: | us-gaap_LossContingencyPatentsAllegedlyInfringedNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of another entity's patents that the entity was found to have infringed. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details
Name: | us-gaap_LossContingencyPatentsFoundInfringedNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of another entity's patents that the entity was found not to have infringed. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details
Name: | us-gaap_LossContingencyPatentsFoundNotInfringedNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ComirnatyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=pfe_AlnylamPatentInfringementCaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=pfe_ModernaTXUSPatentInfringementCaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=pfe_ModernaTXEuropeanPatentInfringementCaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=pfe_ArbutusAndGenevantUSPatentInfringementCaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=pfe_GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCUSPatentInfringementCaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=pfe_GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCIrelandPatentInfringementCaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=pfe_GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCUnifiedPatentCourtPatentInfringementCaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=pfe_PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |